Diabetes is a known risk factor in glaucoma (Khan et al., 2017), and GLP-1R agonists’ wide usage in diabetes treatment presents an opportunity to retrospectively evaluate its effects among patients with coexisting glaucoma in a large-scale observational study. This evidence concerns the gene GLP1R and glaucoma.